{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:23:26Z","timestamp":1780514606293,"version":"3.54.1"},"reference-count":42,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Pharmaceutica NV"},{"name":"Costello Medical, UK"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (EGFR) Exon 20 insertions (Exon20ins) at the second line and beyond (2L+) have an unmet need for new treatment. Amivantamab, a bispecific EGFR- and MET-targeted antibody, demonstrated efficacy in this setting in the phase 1b, open-label CHRYSALIS trial (NCT02609776). The primary objective was to compare the efficacy of amivantamab to the choices made by real-world physicians (RWPC) using an external control cohort from the real-world evidence (RWE) chart review study, CATERPILLAR-RWE. Adjustment was conducted to address differences in prognostic variables between cohorts using inverse probability weighting (IPW) and covariate adjustments based on multivariable regression. In total, 114 patients from CHRYSALIS were compared for 55 lines of therapy from CATERPILLAR-RWE. Baseline characteristics were comparable between the amivantamab and IPW-weighted RWPC cohorts. For amivantamab versus RWPC using IPW adjustment, the response rate ratio for the overall response was 2.14 (p = 0.0181), and the progression-free survival (PFS), time-to-next-treatment (TTNT) and overall survival (OS) hazard ratios (HRs) were 0.42 (p &lt; 0.0001), 0.47 (p = 0.0063) and 0.48 (p = 0.0207), respectively. These analyses provide evidence of clinical and statistical benefits across multiple outcomes and adjustment methods, of amivantamab in platinum pre-treated patients with advanced NSCLC harboring EGFR Exon20ins. These results confirm earlier comparisons versus pooled national registry data.<\/jats:p>","DOI":"10.3390\/cancers15225326","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T03:42:40Z","timestamp":1699501360000},"page":"5326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Amivantamab Compared with Real-World Physician\u2019s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-8980","authenticated-orcid":false,"given":"Petros","family":"Christopoulos","sequence":"first","affiliation":[{"name":"Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, 69126 Heidelberg, Germany"},{"name":"German Center for Lung Research (DZL), 35392 Gie\u00dfen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Institut Curie, Institut du Thorax Curie-Montsouris, 75005 Paris, France"},{"name":"Paris Saclay University, University of Versailles Saint-Quentin-en-Yvelines (UVSQ), 78000 Versailles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-9787","authenticated-orcid":false,"given":"Claudia","family":"Proto","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6071-3673","authenticated-orcid":false,"given":"Marta","family":"Soares","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-6125","authenticated-orcid":false,"given":"Pilar Garrido","family":"Lopez","sequence":"additional","affiliation":[{"name":"Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonie J.","family":"van der Wekken","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-4963","authenticated-orcid":false,"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[{"name":"The Royal Marsden Hospital, London SW3 6JJ, UK"},{"name":"The Institute of Cancer Research, London SW7 3RP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-9120","authenticated-orcid":false,"given":"Joris","family":"Diels","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, 2340 Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-4676","authenticated-orcid":false,"given":"Claudio A.","family":"Schioppa","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, 2340 Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sermon","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, 2340 Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Rahhali","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Ltd., 92130 Issy-les-Moulineaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Pick-Lauer","sequence":"additional","affiliation":[{"name":"Janssen-Cilag GmbH, 41470 Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Adamczyk","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Ltd., 28042 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Penton","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Ltd., High Wycombe HP12 4EG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-7859","authenticated-orcid":false,"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[{"name":"H\u00f4pital Cochin, APHP, 75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hou, J., Li, H., Ma, S., He, Z., Yang, S., Hao, L., Zhou, H., Zhang, Z., Han, J., and Wang, L. (2022). EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: Current status and perspectives. Biomark. Res., 10.","DOI":"10.1186\/s40364-022-00372-6"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2021.10.020","article-title":"Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations","volume":"162","author":"Bazhenova","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Burnett, H., Emich, H., Carroll, C., Stapleton, N., Mahadevia, P., and Li, T. (2021). Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247620"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/03007995.2022.2083326","article-title":"Non-small cell lung cancer with EGFR exon 20 insertion mutation: A systematic literature review and meta-analysis of patient outcomes","volume":"38","author":"Kwon","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9513","DOI":"10.1200\/JCO.2020.38.15_suppl.9513","article-title":"ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions","volume":"38","author":"Piotrowska","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2022.06.012","article-title":"High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial","volume":"170","author":"Zwierenga","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_13","unstructured":"Girard, N., Wolf, J., Kim, T.M., Leighl, N., Knott, C., Li, T., Cabrieto, J., Diels, J., Sermon, J., and Mahadevia, P. (April, January 29). Amivantamab Versus Alternative Real-World Anti-Cancer Therapies in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in the US and Europe. Proceedings of the European Lung Cancer Congress, Copenhagen, Denmark."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s12325-022-02408-7","article-title":"An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations","volume":"40","author":"Chouaid","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_15","unstructured":"European Medicines Agency (EMA) (2023, February 01). European Public Assessment Report: Rybrevant. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybrevant-epar-product-information_en.pdf."},{"key":"ref_16","unstructured":"Food and Drug Administration (2023, March 01). Mobocertinib (EXKIVITY\u2122) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215310s000lbl.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_18","unstructured":"Food and Drug Administration (2023, April 01). Amivantamab (RYBREVANT\u2122) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761210s000lbl.pdf."},{"key":"ref_19","unstructured":"Medicines and Healthcare Products Regulatory Agency (2023, April 01). Rybrevant 50 mg\/mL Concentrate for Solution for Infusion SmPC, Available online: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/431ad859be20738a20096b590eb779bd4e939c67."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e214761","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion\u2013positive metastatic non\u2013small cell lung cancer: A phase 1\/2 open-label nonrandomized clinical trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_21","unstructured":"Medicines and Healthcare Products Regulatory Agency (2023, April 01). EXKIVITY 40 mg Hard Capsules SmPC, Available online: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/5180220753ab1fe3d10b9be546baba0b7f665fa9."},{"key":"ref_22","unstructured":"Takeda (2023, October 18). Takeda Provides Update on EXKIVITY\u00ae (Mobocertinib). Available online: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2023\/Takeda-Provides-Update-on-EXKIVITY-mobocertinib\/."},{"key":"ref_23","unstructured":"(2023, October 18). ClinicalTrials.gov. TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04129502."},{"key":"ref_24","unstructured":"European Medicines Agency (EMA) (2023, March 01). Exkivity: Withdrawal of the Marketing Authorisation Application. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/exkivity."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jtho.2023.01.086","article-title":"Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non-small Cell Lung Cancer","volume":"18","author":"Ou","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jval.2016.12.003","article-title":"Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"key":"ref_28","unstructured":"European Medicines Agency (EMA) (2023, October 26). Talvey Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/talvey-epar-public-assessment-report_en.pdf."},{"key":"ref_29","unstructured":"European Medicines Agency (EMA) (2023, October 26). Carvykti Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/carvykti-epar-public-assessment-report_en.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2022.03.005","article-title":"Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy","volume":"168","author":"Minchom","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using Big Data to Emulate a Target Trial When a Randomized Trial Is not Available","volume":"183","author":"Robins","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: An application to postmenopausal hormone therapy and coronary heart disease","volume":"19","author":"Alonso","year":"2008","journal-title":"Epidemiology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/pst.2107","article-title":"How to choose a time zero for patients in external control arms","volume":"20","author":"Backenroth","year":"2021","journal-title":"Pharm. Stat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/0272989X221096070","article-title":"Approaches to selecting \u201ctime zero\u201d in external control arms with multiple potential entry points: A simulation study of 8 approaches","volume":"42","author":"Hatswell","year":"2022","journal-title":"Med. Decis. Mak."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting","volume":"113","author":"Li","year":"2018","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/sim.2174","article-title":"Adjusted Kaplan\u2013Meier estimator and log-rank test with inverse probability of treatment weighting for survival data","volume":"24","author":"Xie","year":"2005","journal-title":"Stat. Med."},{"key":"ref_37","unstructured":"(2023, March 01). ClinicalTrials.gov. Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants with Advanced Non-Small Cell Lung Cancer (CHRYSALIS), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02609776."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1038\/s41467-022-30908-1","article-title":"Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer","volume":"13","author":"Popat","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2018.21554","article-title":"Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies","volume":"321","author":"Haneuse","year":"2019","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2022.04.020","article-title":"The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions","volume":"170","author":"Christopoulos","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_41","unstructured":"(2023, March 01). ClinicalTrials.gov. A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04538664."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"(2022). Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Ann. Intern. Med., 175, 1298\u20131304.","DOI":"10.7326\/M22-1460"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/22\/5326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:19:27Z","timestamp":1760131167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/22\/5326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":42,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["cancers15225326"],"URL":"https:\/\/doi.org\/10.3390\/cancers15225326","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]}}}